Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada ...
Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
Now the longest lasting and most accurate CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is ...
Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...
Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.
Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results